Kornimate/medical-research-clean huggingface dataset:
myocardial metabolism in patients with dilated cardiomyopathy

Conditions: Dilated Cardiomyopathy; Type 2 Diabetes

Summary: dilated cardiomyopathy (dcm) is characterized by a metabolic shift from fat to carbohydrates and failure to increase myocardial glucose uptake in response to workload increments. the investigators aimed at verifying whether this pattern is influenced by the presence of abnormal glucose tolerance (agt).

a catheter is advanced into the coronary sinus by fluoroscopy to withdraw venous blood. a unipolar pacing catheter is positioned into the right atrium. arterial sampling is done from the femoral artery introducer catheter. the study protocol consisted of 3 steps (rest, pacing and recovery), during which timed blood samples are collected to measure plasma nefa and glucose. after the instrumentation is completed, rest arterio-venous sampling is performed at time -15 min and 0 min. after the 0 min, heart rate is increased by atrial pacing to 110 bpm for 3 minutes and to 130 bpm for 3 additional minutes and arterio-venous sampling is repeated at the end of each step (at time 3 and 6 min). pacing is then stopped and at time 1, 5, 15 and 30 min into the recovery period other pairs of arterial and venous samples are withdrawn.

Eligibility criteria:
inclusion criteria: for patients with dilated cardiomyopathy: * myocardial left ventricular ejection fraction (lvef) \<40% * left ventricular end-diastolic diameter (lvedd) \>56 mm for patients without dilated cardiomyopathy: * lvef \>50% * lvedd \<56 mm. exclusion criteria: * nyha class iv * atrial fibrillation * previous myocardial infarction * valvular heart disease * myocarditis * pericarditis * severe to moderate systemic arterial hypertension * fasting hyperglycaemia (\>7.0 mmol/l) * treated diabetes, autoimmune diseases, neoplasia, kidney, liver or respiratory failure
the wideband acoustic immittance data in thai normal hearing and conductive hearing loss adults

Conditions: Normal Hearing; Conductive Hearing Loss, Middle Ear

Summary: the goal of this descriptive study is to collect the wideband immittance data in thai normal hearing and conductive hearing loss adults. the main questions it aims to answer are: 1. what is normative data of wideband acoustic immittance in thai normal hearing adults 2. what is the wideband acoustic immittance data in thai conductive hearing loss who have type a, as and ad tympanogram participants will examine hearing tests consequently * pure tone audiometry * tympanometry with ipsilateral acoustic reflex * wideband acoustic immittance


Eligibility criteria:
inclusion criteria: normal group 1. thai adults (18-60 years old) 2. pure-tone air-conduction thresholds ≤ 25 db hl, measured at audiometric frequencies 250, 500, 1000, 2000, 3000, 4000, 6000 and 8000 hz and air-bone gab \< 10 dbhl at frequencies 500, 1000, 2000 and 4000 hz 3. type a tympanogram with present ipsilateral acoustic reflex 4. no diagnosis of middle ear disease 5. no history of middle ear surgery 6. normal finding in otoscopic examination conductive hearing loss group 1. thai adults (18-60 years old) 2. pure-tone air-conduction thresholds \> 25 db hl, measured at audiometric frequencies 250, 500, 1000, 2000, 3000, 4000, 6000 and 8000 hz and air-bone gab \> 10 dbhl at frequencies 500, 1000, 2000 and 4000 hz at least 2 frequencies in one ear 3. type a, as or ad tympanogram with absent ipsilateral acoustic reflex 4. normal finding in otoscopic examination 5. there is an appointment for exploration middle ear within 2 months exclusion criteria: 1. have previously had middle ear surgery 2. have an earache 3. type b or c tympanogram 4. volunteers who do not cooperate in audiometry test or unable to do audiometry test

Keywords: wideband acoustic immittance normal hearing thai adults conductive hearing loss absorbance
evaluation of the potential association between 5α-reductase inhibitors prescription and occurrence of high grade prostate cancers

Conditions: Benign Prostate Hyperplasia

Summary: this is a multicenter, cohort study based on medico-administrative data from pathology laboratory registries and drug reimbursement files (cnam-ts).

identification process will be retrospective and prospective using medico-administrative data from all pathology laboratory registries in brittany and drug reimbursement files for patients living in brittany, france. an extraction from drug reimbursement files of french health reimbursement agency (cnam-ts) for patients living in brittany, france will be performed on the following request: reimbursement of any pharmacologic treatment patented for symptomatic benign hyperplasia between january 1st 2010 and december 31st 2011, and no diagnosis of prostate cancer before december 31st, 2011. this extraction has to be done in 2013 to catch data as far as 2010 and will encompass health reimbursement for prostate examination. a second extraction will be done in 2014 to complete data from the end of 2013. secondly, identification of patients will use pathology laboratory registries, based on code for prostate examination (prostate biopsy, prostatectomy or prostate resection); involvement of all pathology laboratories in brittany ensures completeness of collection of prostate examination results for the study period (january 1st, 2012 to december 31st, 2013). a list of patients will be recorded at each pathology laboratory level with date of birth, date of prostate examination, type of exam, results with gleason score along with a study number on electronic file. by january 2014, link to reimbursement file (that is data on all reimbursement within 3 years: 2009 to 2011 previously extracted from the french health reimbursement agency) will be done thanks to three key variables (date of birth, date of prostate examination, identification of pathology laboratory) and all data from all centers will set up into one global file. this design will allow evaluation of association between 5-ari and either high grade prostate cancer or low grade prostate as opposite association could be observed. in addition this design focuses on the target population, i.e. patients with symptomatic benign prostate hyperplasia, identified through reimbursement of drugs patented for symptomatic benign prostate hyperplasia.

Eligibility criteria:
inclusion criteria: * men with a reimbursement of any pharmacologic treatment patented for symptomatic benign prostate hyperplasia between january 1st 2010 and december 31st 2011, affiliated to french health system and living in brittany, france. exclusion criteria: * prostate cancer with a date of diagnosis before december 31st, 2011, patients enrolled in surveillance program with scheduled prostate biopsy, patients not affiliated to french health system.

Keywords: benign prostate hyperplasia 5 alpha reductase inhibitor prostate cancer symptomatic treated
middle cerebral artery doppler in uncomplicated term pregnancy

Conditions: Post Date

Summary: doppler measurements in the middle cerebral artery (mca) is a part of the assessment for assessing fetal well-being in complicated pregnancy, including intra uterine growth retardation and fetal anemia. the use of this doppler measurement in uncomplicated term pregnancies is not a common practice due to lack of information. however, several studies use the mca pulsatility index (pi) as part of the cerebro-placental-ratio (cpr) measurment at term. the purpose of this trial is to assess mca doppler variability in term, uncomplicated pregnancy.

measuring the resistance in the fetal middle cerebral artery (mca) is an important factor in assessing fetal well-being. on its own, the pulsatility index (pi) in the mca may indicate a decrease in fetal oxygenation. furthermore, the pi measured in the fetal mca is an index parameter in the calculation of the cerebro-placental ratio (cpr) used to evaluate whether there is an existing disturbance in the placental-umbilical and feto-cerebral circulations. the cpr is a measurement that enables practitioners to predict the fetuses reaction to intrauterine hypoxemia. the cpr measurement is commonly used to evaluate small for gestational age (sga) fetuses and to distinguish between constitutionally small fetuses and ones that suffer from placental insufficiency. for those who suffer from placental insufficiency, the cpr measurement is an aid in deciding the optimal time and mode of delivery. recently, researchers pondered if the cpr measurement may aid in predicting disturbance in fetal oxygenation during delivery. a number of studies have showed that appropriate for gestational age fetuses with abnormal cpr measurements may be susceptible to delivery complications in the same manner as fetuses who suffer from placental insufficiency. the question that is yet to be answered is whether the mca measurement reliable in term pregnancies. this question arises due to the impression that the mca measurement at term is highly variable, even when taken under optimal conditions. the aim of this study is to evaluate the intra-observer variability in the mca measurement under optimal conditions, in uncomplicated term pregnancies.

Eligibility criteria:
inclusion criteria: uncomplicated term pregnancies exclusion criteria: high risk pregnancies including placental insufficiency, intrauterine growth retardation or any maternal vascular disease.
postural stability, balance and fall risk in patients with obstructive sleep apnea

Conditions: Obstructive Sleep Apnea

Summary: obstructive sleep apnea (osa) is a clinical condition characterized by the repetitive obstruction of the upper airway during sleep, resulting in nocturnal hypoxaemia and fragmented sleep. fragmented sleep leads to daytime sleepiness that causes alterations in reaction times and reflexes . postural stability is an important function of the human body. it is shown that the sleep deprivation disturbs daytime postural stability and balance. aim of this study is to examine the influence of osa severity and daytime sleepiness on postural stability, balance and fall risk.


Eligibility criteria:
inclusion criteria: * subjects with recent diagnosis of osa (ahi≥5) * bmi of ≤35 kg/m2 * being sedentary exclusion criteria: * having osa treatments (cpap, oral devices, nasal surgery, tennis ball/positional therapy, diuretic), * having a disease that can affect balance (vestibular, neurological, orthopedic ...) performing regular exercise * morphological defect (facial malformation, etc.) which may cause sleep disorders * uncontrolled hypertension or arrhythmia * history of smoking or alcoholism * orthopedic, neurological or musculoskeletal problems which impede exercising * pregnancy * uncompensated clinical conditions such as chronic obstructive pulmonary disease, interstitial lung disease, heart failure, or rheumatic and psychiatric diseases
rheumatoid arthritis satisfaction outcome research

Conditions: Rheumatoid Arthritis

Summary: ra satisfaction or: this study aim to compare treatment satisfaction and quality of life between patients who have been using tofacitinib citrate and patients who have been using adalimumab for 6 months or more and less than 2 year in ra treatment of rheumatoid arthritis.

ra satisfaction or: this study aim to compare treatment satisfaction and quality of life between patients who have been using tofacitinib citrate and patients who have been using adalimumab for 6 months or more and less than 2 year in ra treatment of rheumatoid arthritis. study design: non-interventional, multi-centers, cross-sectional study

Eligibility criteria:
inclusion criteria: 1. patients aged 19 years or older 2. patients diagnosed with ra 3. treatment groups: 1) tofacitinib citrate users: patients currently on treatment with tofacitinib citrate in ra therapy for 6 months or more 2) adalimumab users: patients currently on treatment with adalimumab in the ra therapy for 6 months or more 4. reading and writing with enough proficiency to complete assessment instruments in korean exclusion criteria: 1. patients currently on tofacitinib citrate or adalimumab for 2 year or more 2. patients taking azathioprine and cyclosporine 3. patients participating in other drug interventional study 4. patients who have been treated with bdmards except rheumatoid arthritis.
skinpen efficacy on acne scars on the face and/or back

Conditions: Atrophic Acne Scar

Summary: this single-center, clinical trial will take place over a 90 day course followed by 1-month and 6-month post treatment visits to assess the efficacy and tolerability of the skinpen device when used on both men and women on the face and/or back.

at least 20 subjects of varying fitzpatrick skin types will be admitted to the trial for treatment on their moderate to severe acne scars on the face and/or back. implementation of needle depths ranging from 0.25 mm to 2.0 mm will depend on severity of scars and their location. each subject will undergo 3 treatments in 30 day increments and will take pre-treatment images as well as 1-month and 6-months post treatment images. assessment will be based on the goodman and baron's grading system, the clinician's global aesthetic improvement scale, as well as a self-assessment.

Eligibility criteria:
inclusion criteria: * men and women 18 to 60 years of age. * subjects in good health. * approximately 5 to 10 atrophic acne scars of mixed types (boxcar and/or rolling scars with some icepick scars allowed) on face and/or back that are moderate to severe. * desire correction of his/her acne scarring. * subjects of child bearing potential must take a urine pregnancy test and must test negative. * subjects willing to sign a photography release. * willingness to cooperate and participate by following study requirements. exclusion criteria: * allergies to facial or general skin care products * presence of an active systemic or local skin disease. * severe solar elastosis. * sensitivity to topical lidocaine. * recent history of significant trauma to the face (\< 6 months). * significant scarring other than acne scars in treated area(s). * severe of cystic active and clinically significant acne on the area(s) to be treated. * history of systemic granulomatous diseases. * history of hypertrophic or keloid scars. * current cancerous or pre-cancerous lesions in area(s) to be treated. * had microdermabrasion or glycolic acid treatment to treatment area(s) within 1 month prior to study participation. * history of chronic drug or alcohol abuse. * current smokers or have smoked in the last 5 years. * history of cosmetic treatments: skin tightening within last year, injectable filler of any type within the last year, neurotoxins within the last 3 months, ablative resurfacing laser treatments, non-ablative, rejuvanative laser treatments in last 6 months, chemical peel, dermabrasion, non-ablative laser or fractional laser resurfacing of face and neck within the last 4 weeks. * history of certain prescription medications (accutane or other retinoids, topical retinoids, prescription strength skin lightening devices, anti-wrinkle, skin lightening devices, antiplatelet agents/anticoagulants, and/or psychiatric drugs). * nursing, pregnant, or planning to become pregnant during study. * current or pre-existing dermatologic diseases on the face or body (psoriasis, rosacea, eczema, etc.) * history of immunosupression/immune deficiency disorders. * current or history of uncontrolled disease such as asthma, diabetes, hyperthyroidism, etc.
gait and alzheimer interaction tracking (gait) study

Conditions: Gait Apraxia; Alzheimer Disease; Impaired Cognition; Cerebral Atrophy

Summary: the purpose of this study is to examine and to compare gait characteristics under single- and dual-task conditions among healthy subjects together with ad patients at different stages of disease (i.e., pre-dementia, mild and moderate dementia stages).

although gait disorders are frequently associated with alzheimer's disease (ad), few studies have focused on their characterization and mechanism. exploring the associations of the gait characteristics - more particularly the gait variability - with the cognitive performance of ad patients on one hand, and with the morphological brain abnormalities on the other hand, could be useful to understanding the mechanisms of gait disorders in ad. the main objective of this study is to examine and to compare gait characteristics under single- and dual-task conditions among healthy subjects together with ad patients at different stages of disease (i.e., pre-dementia, mild and moderate dementia stages).

Eligibility criteria:
inclusion criteria: * age ≥ 60 years * able to walk without walking aid on 15 metres * score of mini-mental examination (mmse) \> 10 * written informed consent to participate in the study (or trustworthy person) * being affiliated to a social security regime * near visual acuity ≥ 2/10 * absence of severe depression (score in the 15-item geriatric depression scale ≤ 10) exclusion criteria: * score of mini-mental examination (mmse) ≤ 10 * subject suffering from pre-existing impellent disturbances * history of cerebrovascular accident or other cerebro-spinal pathology * poor workmanship of the written or oral french language * refusal of subject to be informed on possible hanging bare anomaly during study * use of walking aid * acute medical or surgical disease in the past 3 months * refusal to participate (or trustworthy person) * contra-indication to the achievement of a magnetic resonance imaging * near visual acuity \< 2/10 * presence of severe depression (score in the 15-item geriatric depression scale \> 10)
a multicenter, open trial with subcutaneous immunotherapy (scit) in patients with rhinoconjunctivitis sensitized to parietaria judaica

Conditions: Rhinoconjunctivitis

Summary: the study was designed according to the draft of allergenic product regulation published by spanish regulatory agency. the aim of the study is to evaluate the safety and tolerability of subcutaneous immunotherapy with parietaria judaica pollen extract in patients with rhinoconjunctivitis with or without associated mild asthma. in addition, surrogate efficacy parameters will be evaluated: immunoglobulin level changes and skin reactivity.

parietaria judaica is a weed widespread throughout the mediterranean área. prevalence of sensitization to parietaria judaica's pollen is very high in the mediterranean areas, reaching 41.4% among allergic patients on the spanish mediterranean coast. the study has been designed as an open trial which will be conducted in 4 spanish sites.

Eligibility criteria:
inclusion criteria: 1. patients must sign the informed consent form. 2. patients must be between 18 and 60 years of age. 3. patients with seasonal allergic rhinoconjunctivitis against parietaria judaica during a minimum of 2 years prior to study participation. although allergic rhinoconjunctivitis is the pathology under study, the inclusion of patients with mild concomitant asthma is allowed (gina 2013). 4. patients who obtained a prick test result ≥ 3 mm diameter to parietaria judacia. positive and negative control of the test should give consistent results. 5. patients with specific immunoglobulin e ≥ class 2 (cap/phadia) to parietaria judaica. 6. patients sensitized to parietaria judaica with clinically relevant symptoms in which treatment with parietaria judaica 100% vaccine is indicated. 7. women of childbearing potential must have a negative urine pregnancy test at screening visit/visit 0. 8. women of childbearing potential must agree to use an appropriate contraception method during the study if they are sexually active. exclusion criteria: 1. patients who received immunotherapy in the previous 5 years for parietaria judaica or fo rany allergen with cross reactivity or patients that are currently receiving immunotherapy for any allergen. 2. patients with severe asthma or forzed expiratoy volumen in 1 second fev1\< 70% even if the are pharmacologically controlled . 3. patients with: immunological, cardiac, renal or hepatic illnesses or any other medical condition that the investigator deems relevant so as to interfere with the study. 4. patients with a previous history of anaphylaxis 5. patients with chronic urticaria, 6. patients with moderate to severe atopic dermatitis 7. patients who have participated in another clinical trial within 3 month prior to enrolment. 8. patients under treatment with tricyclic antidepressives, phenothiazines , β-blockers, or angiotensin converting enzyme inhibitors (acei) 9. female patients who are pregnant or breast-feeding 10. patient who does not attend the visits 11. patient's lack of collaboration or refusal to participate.

Keywords: allergy scit
a study comparing the bioequivalence of ciclesonide nasal spray (apotex, inc.) to that of omnaris™ nasal spray (sepracor, inc.) in the treatment of seasonal allergic rhinitis

Conditions: Seasonal Allergic Rhinitis

Summary: this study is to evaluate the equivalence of generic ciclesonide nasal spray with that of the marketed drug, omnaris™ nasal spray, in the treatment of seasonal allergic rhinitis, and to evaluate the safety and tolerability of generic ciclesonide nasal spray compared with omnaris™ nasal spray.


Eligibility criteria:
inclusion criteria: * if female of childbearing potential, is not pregnant (confirmed by negative urine pregnancy test) or lactating and must have used reliable birth control measures throughout the study. * at least a 2-year reliable medical history consistent with sar * positive skin test within 12 months of screening to at least one seasonal allergen present in the geographical area * capable of tolerating intranasal application of the imp, willing and able to comply with the requirements of the protocol * no clinically significant findings in physical and nasal examinations, and medical history. * a reflective tnss of at least 6 (out of 12) in the 24 hours prior to placebo lead-in visit. * successfully complete the placebo lead-in period. exclusion criteria: * - signs or symptoms of nasal polyps, deviated septum, or any other condition which, in the opinion of the investigator, could resulted in erroneous study data. * undergo nasal surgery or had nasal trauma within 3 months of screening. * active respiratory conditions or respiratory tract infection that require antibiotic treatment within 2 weeks of screening * persistent allergic rhinitis (par) that does not require or not expected to require active par treatment during the study period. * evidence of any unstable or clinically significant conditions that would place the subject at increased risk of complications, interfere with study participation, or confound any of the study objectives. * presence or history of clinically significant conditions which in the opinion of the investigator would have compromised the safety of the subject or the conduct of the study. * use of corticosteroids, intranasal cromolyn, leukotriene inhibitors, long or short acting antihistamines, intranasal or systemic decongestants prior to the start of the single-blind, placebo lead-in visit within the time periods specified in the protocol or receiving immunotherapy. * use of an investigational drug within 30 days before screening or during the study. * known or suspected hypersensitivity to corticosteroids. * inability to avoid exposure to chicken pox or measles. * infection requiring oral antibiotic treatment 2 weeks prior to screening. * previously identified as a placebo responder or known as a non responder to corticosteroids. * history of alcohol, drug, or substance abuse in the 12 months prior to visit 1 (screening). * positive for hepatitis b or c, or human immunodeficiency virus (hiv). * uncooperative or non compliant. * female subjects who planned to become pregnant during the conduct of the study. * current smoker (former smokers had to be 6 months smoke free).